Compare Fresenius Kabi Onco. with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PFIZER - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PFIZER FRESENIUS KABI ONCO./
PFIZER
 
P/E (TTM) x 22.1 49.2 45.0% View Chart
P/BV x 3.1 8.2 38.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   PFIZER
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PFIZER
Mar-19
FRESENIUS KABI ONCO./
PFIZER
5-Yr Chart
Click to enlarge
High Rs1763,840 4.6%   
Low Rs792,080 3.8%   
Sales per share (Unadj.) Rs37.7455.0 8.3%  
Earnings per share (Unadj.) Rs5.193.8 5.4%  
Cash flow per share (Unadj.) Rs6.7109.4 6.1%  
Dividends per share (Unadj.) Rs022.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5658.2 6.5%  
Shares outstanding (eoy) m158.2345.75 345.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.5 51.9%   
Avg P/E ratio x25.031.6 79.2%  
P/CF ratio (eoy) x18.927.1 69.9%  
Price / Book Value ratio x3.04.5 66.5%  
Dividend payout %024.0 0.0%   
Avg Mkt Cap Rs m20,135135,420 14.9%   
No. of employees `0001.22.6 43.8%   
Total wages/salary Rs m7033,238 21.7%   
Avg. sales/employee Rs Th5,176.27,911.4 65.4%   
Avg. wages/employee Rs Th610.41,230.9 49.6%   
Avg. net profit/employee Rs Th699.61,630.7 42.9%   
INCOME DATA
Net Sales Rs m5,96320,815 28.6%  
Other income Rs m181,674 1.1%   
Total revenues Rs m5,98122,489 26.6%   
Gross profit Rs m1,4305,712 25.0%  
Depreciation Rs m258714 36.1%   
Interest Rs m-2673 -35.7%   
Profit before tax Rs m1,2166,599 18.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,309 14.8%   
Profit after tax Rs m8064,291 18.8%  
Gross profit margin %24.027.4 87.4%  
Effective tax rate %28.135.0 80.4%   
Net profit margin %13.520.6 65.6%  
BALANCE SHEET DATA
Current assets Rs m5,10227,167 18.8%   
Current liabilities Rs m2,3858,917 26.8%   
Net working cap to sales %45.687.7 52.0%  
Current ratio x2.13.0 70.2%  
Inventory Days Days15068 221.3%  
Debtors Days Days11330 376.4%  
Net fixed assets Rs m5,1488,862 58.1%   
Share capital Rs m158458 34.6%   
"Free" reserves Rs m6,55629,656 22.1%   
Net worth Rs m6,73230,113 22.4%   
Long term debt Rs m95225 3,808.8%   
Total assets Rs m10,38839,400 26.4%  
Interest coverage x-45.891.5 -50.0%   
Debt to equity ratio x0.10 17,037.9%  
Sales to assets ratio x0.60.5 108.7%   
Return on assets %7.511.1 67.8%  
Return on equity %12.014.2 84.0%  
Return on capital %14.622.1 66.0%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298428 1,236.9%   
Fx outflow Rs m1,772786 225.4%   
Net fx Rs m3,525-358 -984.5%   
CASH FLOW
From Operations Rs m1,274978 130.3%  
From Investments Rs m-1,204351 -342.9%  
From Financial Activity Rs m-196-1,099 17.9%  
Net Cashflow Rs m-126231 -54.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 63.9 126.8%  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 9.6 4.9 195.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.7 38.4%  
Shareholders   42,599 85,207 50.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WYETH  IPCA LABS  NATCO PHARMA  NEULAND LABS  PIRAMAL ENTERPRISES  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower, Dow Futures Down by 128 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 328 points, down 0.7% at 48,833 levels.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS